Physician profile
Amber Webb
NPI 1962980268
$1,774.60
in general payments reported to CMS, 2019-2025
27 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $208 · 2023: $360 · 2024: $384 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.89 | 2021-2025 | |
| Lilly USA, LLC | $172.86 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $171.13 | 2021-2025 | Ozempic, Rybelsus, Saxenda |
| Otsuka America Pharmaceutical, INC. | $124.83 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $120.82 | 2024-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.68 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $85.34 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.20 | 2021 | |
| Glaxosmithkline, LLC. | $61.55 | 2021-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $48.07 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.24 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $36.91 | 2021 | |
| Abbott Laboratories | $34.21 | 2021-2022 | |
| Lundbeck LLC | $33.67 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.01 | 2022-2024 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.75 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $27.62 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $22.81 | 2025 | Hetlioz, Fanapt |
| Globus Medical, INC. | $21.63 | 2025 | Senza |
| Dexcom, INC. | $18.52 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.29 | 2025 | Gemtesa |
| Antares Pharma, INC. | $16.68 | 2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $15.67 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $14.85 | 2022 | |
| Nevro Corp. | $14.20 | 2022 | |
| Esperion Therapeutics, INC. | $12.50 | 2021 | |
| Amgen INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.